Phase 3 Prostate Cancer Trial, Recruiting NCT05169112 Sponsor: Ottawa Hospital Research Institute Condition: Prostate Cancer
Back to Prostate Cancer

Phase 3 Prostate Cancer Trial, Recruiting

NCT05169112
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who had prostate surgery and had a PSA level that was undetectable (below 0.02 ng/ml) within 16 weeks after the operation.
  • People whose risk of PSA returning within 5 years of surgery is calculated at 25% or higher, based on a specific medical scoring tool called the Kattan nomogram.

Who may not be able to join:

  • People who are not willing to receive hormone therapy (called ADT, which works by reducing testosterone levels).
  • People who have already received hormone therapy (ADT) in the past.
  • People whose cancer has spread to the lymph nodes.
  • People who have a known allergy to any form of hormone therapy (ADT).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 613-737-8899

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Ottawa Hospital Research Institute
Registry
ClinicalTrials.gov
Start date
6 March 2023
Est. completion
1 November 2026

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Rate of enrolment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov